Cellular Biomedicine Group Company Profile (NASDAQ:CBMG)

About Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group logoCellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CBMG
  • CUSIP: N/A
  • Web: www.cellbiomedgroup.com
Capitalization:
  • Market Cap: $135.44 million
  • Outstanding Shares: 14,108,000
Average Prices:
  • 50 Day Moving Avg: $10.39
  • 200 Day Moving Avg: $9.24
  • 52 Week Range: $5.05 - $15.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.19
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $229,178.00
  • Price / Sales: 590.97
  • Book Value: $3.91 per share
  • Price / Book: 2.46
Profitability:
  • EBITDA: ($22,450,000.00)
  • Net Margins: -12,736.68%
  • Return on Equity: -41.33%
  • Return on Assets: -39.53%
Debt:
  • Current Ratio: 6.50%
  • Quick Ratio: 6.50%
Misc:
  • Average Volume: 23,737 shs.
  • Beta: 2.64
  • Short Ratio: 8.06
 

Frequently Asked Questions for Cellular Biomedicine Group (NASDAQ:CBMG)

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How will Cellular Biomedicine Group's stock buyback program work?

Cellular Biomedicine Group announced that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $10,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its stock is undervalued.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) posted its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). The company had revenue of $0.06 million for the quarter. Cellular Biomedicine Group had a negative net margin of 12,736.68% and a negative return on equity of 41.33%. View Cellular Biomedicine Group's Earnings History.

When will Cellular Biomedicine Group make its next earnings announcement?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Cellular Biomedicine Group.

Where is Cellular Biomedicine Group's stock going? Where will Cellular Biomedicine Group's stock price be in 2017?

1 analysts have issued 12-month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $18.00 to $18.00. On average, they expect Cellular Biomedicine Group's stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Cellular Biomedicine Group.

Who are some of Cellular Biomedicine Group's key competitors?

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:

  • Terry A. Belmont, Chairman of the Board
  • Bizuo Liu, Chief Executive Officer, Interim Chief Financial Officer, Secretary
  • Xia Meng, Chief Operating Officer
  • Yihong Yao Ph.D., Chief Scientific Officer
  • Richard L. Wang Ph.D., Chief Operation Officer
  • Zhou Hansheng, Director
  • Gerardus A. Hoogland, Director
  • Gang Jacky Ji, Director
  • Hansheng Zhou, Non-Executive Director
  • Chun Kwok Alan Au, Independent Director

How do I buy Cellular Biomedicine Group stock?

Shares of Cellular Biomedicine Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of Cellular Biomedicine Group stock can currently be purchased for approximately $9.60.


MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cellular Biomedicine Group (NASDAQ:CBMG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (87.50% upside)
Consensus Price Target History for Cellular Biomedicine Group (NASDAQ:CBMG)
Price Target History for Cellular Biomedicine Group (NASDAQ:CBMG)
Analysts' Ratings History for Cellular Biomedicine Group (NASDAQ:CBMG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017Maxim GroupSet Price TargetBuy$18.00HighView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Cellular Biomedicine Group (NASDAQ:CBMG)
Earnings by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Earnings History by Quarter for Cellular Biomedicine Group (NASDAQ CBMG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.48)N/AView Earnings Details
3/14/2017Q4 2016($0.43)($0.43)$0.06 millionViewN/AView Earnings Details
8/9/2016Q216($0.52)$0.07 millionViewN/AView Earnings Details
3/14/2016Q415($0.42)($0.43)$1.50 million$0.62 millionViewN/AView Earnings Details
11/13/2015Q3($0.43)($0.44)$0.63 millionViewN/AView Earnings Details
8/14/2015Q215($0.37)($0.44)$0.66 millionViewN/AView Earnings Details
5/18/2015Q115($0.40)($0.39)$0.60 millionViewN/AView Earnings Details
3/31/2015($0.32)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)
Current Year EPS Consensus Estimate: $-1.56 EPS
Next Year EPS Consensus Estimate: $-1.55 EPS

Dividends

Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cellular Biomedicine Group (NASDAQ:CBMG)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 5.76%
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Institutional Ownership by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2017Tony LiuCEOBuy10,000$6.83$68,300.00View SEC Filing  
2/22/2016Andrew K ChanSVPSell1,307$18.22$23,813.54View SEC Filing  
2/17/2016Andrew K. ChanSVPSell1,516$17.76$26,924.16View SEC Filing  
1/21/2016Andrew K. ChanSVPSell2,812$12.90$36,274.80View SEC Filing  
12/21/2015Andrew K. ChanSVPSell12,812$21.94$281,095.28View SEC Filing  
11/23/2015Andrew K. ChanSVPSell5,332$20.64$110,052.48View SEC Filing  
10/21/2015Wei (William) CaoCEOSell20,000$19.59$391,800.00View SEC Filing  
10/20/2015Andrew K. ChanSVPSell5,215$20.20$105,343.00View SEC Filing  
9/21/2015Andrew K. ChanSVPSell27,927$20.80$580,881.60View SEC Filing  
12/23/2014Pak To LeungMajor ShareholderSell142,857$14.00$1,999,998.00View SEC Filing  
6/26/2014David BolocanDirectorBuy10,000$5.00$50,000.00View SEC Filing  
5/22/2014Tony LiuCFOBuy100,000$5.00$500,000.00View SEC Filing  
7/23/2013Keith WongDirectorSell320,050$0.13$41,606.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cellular Biomedicine Group (NASDAQ:CBMG)
Latest Headlines for Cellular Biomedicine Group (NASDAQ:CBMG)
Source:
DateHeadline
businesswire.com logoCerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center
www.businesswire.com - October 19 at 10:31 PM
seekingalpha.com logoCellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 30 at 1:05 PM
finance.yahoo.com logoCellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
finance.yahoo.com - September 22 at 10:19 AM
finance.yahoo.com logoOne Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG)
finance.yahoo.com - September 20 at 5:45 PM
finance.yahoo.com logoCellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 5:43 PM
seekingalpha.com logoThis Chinese CAR-T Play is Worth Checking Out
seekingalpha.com - September 7 at 10:05 PM
finance.yahoo.com logoETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:35 PM
americanbankingnews.com logoMaxim Group Reiterates "$18.00" Price Target for Cellular Biomedicine Group, Inc. (CBMG)
www.americanbankingnews.com - August 29 at 1:04 PM
finance.yahoo.com logoCellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:03 PM
finance.yahoo.com logoStreetwise Reports Examines One Regenerative Medicine Firm to 'Keep a Close Eye On'
finance.yahoo.com - August 18 at 5:06 PM
americanbankingnews.com logoCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Given a $18.00 Price Target at Maxim Group
www.americanbankingnews.com - August 9 at 6:46 PM
finance.yahoo.com logoCellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights
finance.yahoo.com - August 8 at 4:43 PM
americanbankingnews.com logoCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
americanbankingnews.com logoCellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June
www.americanbankingnews.com - July 16 at 7:06 AM
finance.yahoo.com logoETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:59 PM
streetinsider.com logoCellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
www.streetinsider.com - June 26 at 9:53 PM
reuters.com logoBRIEF-Cellular Biomedicine Group announces stock repurchase program
www.reuters.com - June 1 at 9:43 PM
streetinsider.com logoCellular Biomedicine Group (CBMG) Announces $10M Buyback Program
www.streetinsider.com - June 1 at 9:43 PM
nasdaq.com logoCellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20
www.nasdaq.com - May 19 at 8:52 AM
reuters.com logoBRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
www.reuters.com - May 15 at 3:53 PM
reuters.com logoBRIEF-Cellular Biomedicine Q1 net loss per share $0.43
www.reuters.com - May 8 at 9:06 PM
marketbeat.com logoCellular Biomedicine reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
seekingalpha.com logoIs Cellular Biomedicine Group A Buy?
seekingalpha.com - March 26 at 10:49 AM
reuters.com logoBRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
www.reuters.com - March 15 at 2:06 AM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 14 at 9:04 PM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 14 at 11:12 AM
us.rd.yahoo.com logoCellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress
us.rd.yahoo.com - March 14 at 11:12 AM
benzinga.com logoExclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market
www.benzinga.com - March 4 at 1:35 AM
us.rd.yahoo.com logoCellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.
us.rd.yahoo.com - March 1 at 10:29 AM
seekingalpha.com logoCellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 15 at 2:52 AM
nasdaq.com logoCellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February
www.nasdaq.com - February 8 at 3:18 AM
feeds.benzinga.com logoCellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017
feeds.benzinga.com - February 7 at 9:19 AM
streetinsider.com logoCellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in China
www.streetinsider.com - January 9 at 10:21 PM
nasdaq.com logoCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult
www.nasdaq.com - January 9 at 10:21 PM
us.rd.yahoo.com logoCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China
us.rd.yahoo.com - January 9 at 9:00 AM
us.rd.yahoo.com logo8:00 am Cellular Biomedicine announces three-month interim safety data from Phase I Clinical Trial for AlloJoin off-the-shelf allogeneic stem cell therapy for knee osteoarthritis
us.rd.yahoo.com - December 10 at 11:39 AM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - December 8 at 4:56 PM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 30 at 7:01 AM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements
biz.yahoo.com - November 15 at 10:44 AM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 8 at 2:49 PM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,
biz.yahoo.com - September 22 at 9:45 AM
biz.yahoo.com logoCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation
biz.yahoo.com - September 10 at 8:48 AM
streetinsider.com logoCellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
www.streetinsider.com - August 10 at 11:46 AM

Social

Chart

Cellular Biomedicine Group (CBMG) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.